Pfizer announced that it has selected its preferred once-daily modified release formulation of danuglipron, a move that is ...

Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, ...

Pfizer Inc. announced on Thursday that it will move forward with the testing of its modified version of the once-daily weight ...

Pfizer announced Thursday plans to move forward with an oral daily weight loss medication in the same drug category as ...

(Reuters) -Pfizer plans to move a reworked, once-a-day version of its weight loss pill, danuglipron, into clinical trials ...

Pfizer inadvertently gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release ...

After leading Pfizer’s R&D unit through the pandemic, Chief Scientific Officer Mikael Dolsten, M.D., Ph.D., is heading out.

Pfizer said it saw “encouraging” data from an ongoing early stage trial of its oral weight loss drug, danuglipron.

Pfizer’s stock gained ground early Thursday after the drug company said it has taken a step forward in developing a ...

Pfizer is looking to challenge leaders Eli Lilly and Novo Nordisk in the fast-growing market for weight loss drugs. Pfizer ...

Pfizer shares rose nearly 3% before paring back in early trading in New York.

Pfizer's new weight-loss pill, danuglipron, shows promising results in ongoing study, with plans for dose optimization in ...